Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea

The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales in the process.